Introduction:
Hyperlipidemic and thrombotic events are the most common risk factors for death related to cardiovascular diseases. γ-Oryzanol (OZ) is the active chemical constituent of Oryza sativa bran oil. It is reported for its antihyperlipidemic activity.

Aim:
Our study was aimed to evaluate effect of OZ on atherothrombotic events, i.e. hyperlipidemia and thrombosis in animal model.

Material and methods:
Swiss albino male mice were divided into four groups. Animals were treated with atorvastatin (2 mg/kg, p.o., as the standard drug) and OZ (100 mg/kg, p.o.) up to 3 days. On the 3rd day poloxamer-407 (500 mg/kg, i.p.) was administered to induce hyperlipidemia. Thrombotic plaque was induced using FeCl3 (50%). Animals were sacrificed after 24 h from induction of hyperlipidemia. Blood was collected for estimation of lipid profile, coronary disease risk factors, blood coagulation parameters i.e. APTT and PT. Liver was isolated for estimation of oxidative stress parameters. Further, the effect of therapy on thrombus formation was observed by histopathology of carotid artery.

Results and discussion:
Treatment with OZ was found to improve the serum lipid profile, reduce coronary risk factors, and to decrease oxidative stress. Thrombus formation was found to be reduced on histopathological examination. OZ prolonged APTT and PT.

Conclusions:
OZ found to be therapeutically efficient in hyperlipidemic and atherosclerotic risk management in the animals which may be due to its anti-oxidative stress activity.